Phone:020-31155029| Tech Support:tech@tomums.cn| E-mail:sales@tomums.cn
首页 > 产品 > 活性小分子 > Epigenetics > Tazemetostat (EPZ-6438)

Tazemetostat (EPZ-6438)

商品编号: TS0137
图示 货号 库存 价格(¥) 数量

备注:

如需更大包装,请联系销售人员,大包装有极大的折扣优惠!

质量文档

详细介绍

l  基本信息

产品名称

Tazemetostat (EPZ-6438)

一般描述

Tazemetostat (EPZ-6438) is a potent, and selective EZH2 inhibitor.

别 称

N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide; E7438

纯 度

≥98.0%(HPLC)

CAS NO.

1403254-99-8

分子式

C34H44N4O4

分子量

572.74

适用范围

生物试剂,适用于细胞培养等

l  理化信息

外 观

固体

溶解性(25)

DMSO

~5mg/mL(warmed)

乙醇

Insoluble

Insoluble

l  生物学信息

生物活性/药理作用

Tazemetostat is an orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2, with potential antineoplastic activity. Upon oral administration, tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2 mutated cancer cells. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation.

Tazemetostat (EPZ-6438) is a potent, and selective EZH2 inhibitor with Ki and IC50 of 2.5 nM and 11 nM in cell-free assays, exhibiting a 35-fold selectivity versus EZH1 and >4,500-fold selectivity relative to 14 other HMTs.

l  存储

存储温度

-20

l  注意事项及免责声明

本产品仅用于实验研究,不得作为药物使用,不得用于家用或其它用途。

l  参考文献

1.    http://www.drugbank.ca

2.    https://ncit.nci.nih.gov

3.    https://www.ncbi.nlm.nih.gov